SCYNEXIS INC
SCYXDrugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Aug 12, 2026
8dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
SCYX Earnings Report
EPS Est: $-0.40 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How SCYX's past catalysts played out
SCY-078
Mycoses
Ibrexafungerp
Candida Vulvovaginitis
Fluconazole Tablet
Recurrent Vulvovaginal Candidiasis
SCY-635
Hepatitis C Infection
Fluconazole
Vulvovaginal Candidiasis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SCY-078 | Phase 3 | Mycoses | - | - |
Ibrexafungerp | Phase 3 | Candida Vulvovaginitis | - | - |
Fluconazole Tablet | Phase 3 | Recurrent Vulvovaginal Candidiasis | - | - |
SCY-635 | Phase 2 | Hepatitis C Infection | - | - |
Fluconazole | Phase 2 | Vulvovaginal Candidiasis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in SCYNEXIS INC's drug pipeline?→
CatalystAlert tracks 5 drug candidates in SCYNEXIS INC's (SCYX) pipeline across Phase 3, Phase 2. Its lead program is SCY-078 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SCYNEXIS INC's next FDA catalyst?→
SCYNEXIS INC's (SCYX) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SCYX biotech catalysts?→
Add SCYX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SCYNEXIS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.